ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
NextCure Inc

NextCure Inc (NXTC)

1.34
0.02
( 1.52% )
Updated: 13:02:07

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.34
Bid
1.32
Ask
1.35
Volume
112,515
1.29 Day's Range 1.39
0.98 52 Week Range 2.57
Market Cap
Previous Close
1.32
Open
1.35
Last Trade
77
@
1.34
Last Trade Time
13:01:58
Financial Volume
$ 150,028
VWAP
1.3334
Average Volume (3m)
139,912
Shares Outstanding
27,903,027
Dividend Yield
-
PE Ratio
-0.60
Earnings Per Share (EPS)
-2.25
Revenue
-
Net Profit
-62.72M

About NextCure Inc

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each in... NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
NextCure Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NXTC. The last closing price for NextCure was $1.32. Over the last year, NextCure shares have traded in a share price range of $ 0.98 to $ 2.57.

NextCure currently has 27,903,027 shares outstanding. The market capitalization of NextCure is $37.39 million. NextCure has a price to earnings ratio (PE ratio) of -0.60.

NXTC Latest News

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51%Of the 7 evaluable ovarian cancer patients, there...

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately...

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) --  NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC...

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.14-9.459459459461.481.671.28672191.47537092CS
4-0.31-18.78787878791.651.731.21802991.50516772CS
12-0.56-29.47368421051.92.571.141399121.77911942CS
260.1714.52991452991.172.571.11922671.66439221CS
52-0.28-17.28395061731.622.570.981293671.58066771CS
156-6.56-83.03797468357.99.180.981540964.06930652CS
260-14.1-91.321243523315.441090.9823728516.6520291CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRDIGRIID Infrastructure Inc
$ 1.51
(169.64%)
122.15M
ZAPPZapp Electric Vehicles Group Ltd
$ 3.075
(126.10%)
76.01M
MGOLMGO Global Inc
$ 0.7657
(67.04%)
149.82M
RELIReliance Global Group Inc
$ 0.5671
(45.00%)
114.7M
SMXSMX Security Matters Public Company
$ 0.1612
(35.46%)
162.76M
WHLRWheeler Real Estate Investment Trust Inc
$ 2.74
(-82.57%)
124.38k
KAVLKaival Brands Innovations Group Inc
$ 2.895
(-35.67%)
884.77k
TRVNTrevena Inc
$ 0.23975
(-32.35%)
36.81M
MBIOMustang Bio Inc
$ 0.58
(-31.77%)
34.39M
NLSPNLS Pharmaceutics Ltd
$ 0.1906
(-29.43%)
12.53M
NVDANVIDIA Corporation
$ 131.4059
(-3.08%)
324M
NKLANikola Corporation
$ 0.3521
(-26.78%)
182.49M
SMXSMX Security Matters Public Company
$ 0.1612
(35.46%)
162.76M
MGOLMGO Global Inc
$ 0.7657
(67.04%)
149.82M
GRDIGRIID Infrastructure Inc
$ 1.51
(169.64%)
122.15M

NXTC Discussion

View Posts
TrendTrade2016 TrendTrade2016 3 months ago
NXTC...A MINI BIO BEAST SETTING UP TO BEAST TROUGH WALL STREET!!
👍️0
Monksdream Monksdream 3 months ago
NXTC under $2=
👍️0
Monksdream Monksdream 4 months ago
NXTC new 52 week high
👍️0
Monksdream Monksdream 4 months ago
NXTC under $2
👍️0
Monksdream Monksdream 9 months ago
NXTC under $2
👍️0
conix conix 2 years ago
NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

BELTSVILLE, Md., June 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at the 2022 ECM Pharmacology Congress in Copenhagen that demonstrated NC410 remodels tumor ECM, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model.

The presentation, titled “NC410 (LAIR-2-Fc Fusion Protein): Overcoming Clinical Limitations to Immunotherapy Through Targeting and Remodeling Tumor ECM,” details a study of NC410 that showed by binding collagen in the tumor microenvironment, NC410 was able to remodel the architecture of the tumor ECM and restore normal immune function. ECM remodeling was associated with an enhancement of immune cell infiltration, increased activation of CD8+ T cells, repolarization of suppressive macrophages and a reduction in tumor growth.
“Collagen in the tumor ECM is a potent immunosuppressor, creates a physical barrier to immune cell penetration and is correlated with resistance to currently available immunotherapies. Our data show that NC410 has a unique and novel mechanism to overcome collagen-mediated resistance by remodeling tumor ECM architecture,” said Sol Langermann, Ph.D., NextCure’s chief scientific officer. “NC410 has repeatedly demonstrated the ability to bind to collagen in tumor ECM and remodel the architecture, which enables immune cell infiltration and activation and allows T cells to effectively fight cancer. We look forward to continuing the evaluation of NC410 in our ongoing Phase 1/2 study and investigating biomarkers from patient samples for evidence of ECM remodeling and immune cell activity.”

Highlights of the data presented include:

NC410 binds to collagen-rich areas where LAIR-1+ immune cells are localized.

NC410 promotes ECM remodeling and reduces tumor growth in humanized mouse tumor models.

NC410 synergizes with PD-L1 targeting and provides long-term tumor-specific protection not achieved with individual compounds.

NC410 is currently being evaluated in a Phase 1/2 study in subjects with advanced or metastatic solid tumors. An update to the Phase 1 portion of the trial will be provided in the second half of 2022.
About NC410
NC410 is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells, a type of antigen presenting cell. In preclinical research, it has been shown that LAIR-1 inhibits T cell function and myeloid activity. In preclinical studies, NC410 blocks the negative effects of LAIR-1 and promotes T cell function and myeloid cell activity. NextCure believes NC410 has the potential to treat multiple cancer types.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives, and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
👍️0
ClayTrader ClayTrader 5 years ago
* * $NXTC Video Chart 11-05-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
europtiger europtiger 5 years ago
Buying 78... stop 64
👍️0
stock1ace1 stock1ace1 5 years ago
Short
👍️0
PennyDad PennyDad 5 years ago
These can be tricky when they keep halting like this. Hard to keep track of how far it will drop each time it resumes. At least it is for me anyway.
👍️0
rocco_p_coletrain rocco_p_coletrain 5 years ago
Insane gains here.
👍️0

Your Recent History

Delayed Upgrade Clock